profit from every IDR 100 of sales.
IDR 0IDR 100
PT Kalbe Farma Tbk.
IDR 760.00-0.65% today
-34.5% in 1 year
1-year low IDR 655.001-year high IDR 1,230.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay IDR 9.37 for every IDR 1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
PT Kalbe Farma Tbk. vs. similar companies
PT Kalbe Farma Tbk. grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from IDR 100 of sales | Sales growth a year | Price per IDR 1 of profit |
|---|---|---|---|
| PT Kalbe Farma Tbk. | 9.4× · Cheap | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads PT Kalbe Farma Tbk.'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 9.4×
- –
- 2.71
- 1.4×
- 1.0×
- 14.0×
- –
- 7.2%
- 10.7%
- –
Profitability
- 39.3%
- 12.9%
- 10.4%
- –
- 15.9%
- 14.9%
- –
- –
- –
- –
Growth
- +6.9%
- +3.5%
- –
- –
- −0.7%
Financial health
- -0.8×
- 0.01
- –
- 136.6×
- 3.47
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 13%of 952
Top 41%of 884
Top 9%of 601
Bottom 38%of 887
Top 13%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
71Pass
Benjamin Graham
89Pass
Philip Fisher
51No pass
Peter Lynch
28No pass
Joel Greenblatt
62Pass
Charlie Munger
57No pass
Terry Smith
42No pass
Questions about PT Kalbe Farma Tbk.
Is PT Kalbe Farma Tbk. a good stock to buy?
A solid business, and the price looks low. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PT Kalbe Farma Tbk. AI analysis
What does PT Kalbe Farma Tbk. do?
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. It is in Drug Manufacturers - General.
Is PT Kalbe Farma Tbk. stock halal?
Yes. PT Kalbe Farma Tbk. passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has PT Kalbe Farma Tbk. stock done over the past year?
Down 34.5% over the past twelve months, to IDR 760.00. It traded between IDR 655.00 and IDR 1,230.00 and is 38.2% below its high.
Who are PT Kalbe Farma Tbk.'s competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with PT Kalbe Farma Tbk.'s.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.